Atossa Genetics to Present at the 25th Annual ROTH Conference

Atossa Genetics to Present at the 25th Annual ROTH Conference 
SEATTLE, WA -- (Marketwire) -- 03/06/13 --   Atossa Genetics, Inc.
(NASDAQ: ATOS), The Breast Health Company(TM), announced today that
Steven C. Quay, M.D., Ph.D., FCAP, chairman, CEO & president, and
Kyle Guse, CFO and general counsel, will present the Company's
business model, growth strategy and products and services at the 25th
Annual ROTH Conference at the Ritz-Carlton Laguna Niguel in Dana
Point, California, on Tuesday, March 19, 2013, at 3:30 pm Pacific
Time. 
Dr. Quay commented, "This is Atossa's first time presenting at this
much anticipated event. We appreciate the opportunity afforded to us
to discuss our growth strategy and provide an update on the national
rollout of our ForeCYTE Breast Health Test, which is a highly
significant development that positions Atossa for accelerated growth
in 2013 and beyond. In addition, the rollout of the ArgusCYTE Breast
Health Test and launch of the FullCYTE and NextCYTE breast health
tests, as well as securing a partner for clinical development of our
intraductal therapy this year, each represent significant upside
potential in 2013." 
About Atossa Genetics, Inc. 
Atossa Genetics, Inc. (NASDAQ: ATOS), The Breast Health Company(TM),
is based in Seattle, WA, and is focused on preventing breast cancer
through the commercialization of patented, FDA-cleared diagnostic
medical devices and patented, laboratory developed tests (LDT) that
can detect precursors to breast cancer up to eight years before
mammography, and through research and development that will permit it
to commercialize treatments for pre-cancerous lesions. 
The National Reference Laboratory for Breast Health (NRLBH), a wholly
owned subsidiary of Atossa Genetics, Inc., is a CLIA-certified
high-complexity molecular diagnostic laboratory located in Seattle,
WA, that provides the patented ForeCYTE Breast Health Test, a risk
assessment test for women 18 to 73 years of age akin to the Pap
Smear, and the ArgusCYTE Breast Health Test, a blood test for
recurrence in breast cancer survivors that provides a "liquid biopsy"
for circulating cancer cells and a tailored treatment plan for
patients and their caregivers. 
Forward-Looking Statements 
Except for the historical information contained herein, t
he matters
set forth in this press release, including statements regarding
Atossa's plans, regulatory actions, Atossa's responses to regulatory
actions, expectations, projections, potential opportunities, goals
and objectives are forward-looking statements within the meaning of
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. These forward-looking statements are subject to
risks and uncertainties that may cause actual results to differ
materially from the anticipated or estimated future results,
including the risks and uncertainties associated with actions by the
FDA, regulatory clearances, responses to regulatory matters, Atossa's
ability to continue to manufacture and sell its products, the
efficacy of Atossa's products and services, the market demand for and
acceptance of Atossa's products and services and other risks detailed
from time to time in the Atossa's, filings including its registration
statement form S-1 filed January 28, 2013, as amended and
supplemented from time to time. All forward-looking statements are
qualified in their entirety by this cautionary statement, and Atossa
undertakes no obligation to revise or update any forward-looking
statement to reflect events or circumstances after the issuance of
this press release. 
Contact: 
Atossa Genetics, Inc.
Steven C. Quay, M.D., Ph.D., FCAP 
Chairman, President and CEO of Atossa Genetics and 
Director of the National Reference Laboratory for Breast Health
800-351-3902
Steven.Quay@AtossaGenetics.com 
Dante Ruffalo
Dian Griesel Inc.
212-825-3210
druffalo@dgicomm.com